Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Esophageal Cancer | Research

Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels

Authors: Takahiro Arasawa, Takaki Hiwasa, Akiko Kagaya, Tetsuro Maruyama, Masaya Uesato, Masayuki Kano, Sohei Kobayashi, Hirotaka Takizawa, Katsuro Iwase, Fumio Nomura, Kazuyuki Matsushita, Hisahiro Matsubara

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Colorectal cancer (CRC) is the third most prevalent cancer in the world, yet the sensitivity and specificity of biomarkers for CRC diagnosis are insufficient. In the present study, we performed a protein microarray screening method to identify antibody markers for CRC. Inhibitor of growth family 1 (ING1) was identified as a candidate tumor antigen for CRC using protein microarrays (ProtoArray). Subsequent amplified luminescence proximity homogeneous assay-linked immunosorbent assay using recombinant ING1 protein showed that the serum levels of anti-ING1 antibodies were increased not only in patients with CRC but also in those with esophageal cancer (EC), gastric cancer (GC), breast cancer (BrC), and pancreatic cancer (PC) compared with those of healthy donors (HDs). Antibodies against the ING1 amino acids between 239 and 253 were present at significantly higher levels in patients with CRC than in those with EC, GC, BrC, or PC. Anti-ING1 antibody levels were significantly higher in the patients with CRC at any stages than in the HDs. Immunohistochemical staining revealed higher expression of ING1 protein in CRC cells than in the adjacent normal tissues. In luciferase reporter assays using a CRC cell line, ING1 augmented p53-mediated NOXA promoter activity but attenuated p53-stimulated Bax, p21, and PUMA promoter activities. Consequently, serum anti-ING1 antibodies can be used for sensitive and specific diagnoses of CRC.
Appendix
Available only for authorised users
Literature
1.
2.
Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing Mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71 (PMID: 8474513).CrossRefPubMed
3.
Zamcheck N, Pusztaszeri G. CEA, AFP and other potential tumor markers. CA Cancer J Clin. 1975;25:204–14 (PMID: 48409).CrossRefPubMed
4.
Kuusela P, Jalanko H, Roberts P, Sipponen P, Mecklin JP, Pitkänen R, Mäkelä O. Comparison of CA 19–9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer. 1984;49:135–9 (PMID: 6582896).CrossRefPubMedPubMedCentral
5.
Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83 (PMID: 11042560).CrossRefPubMed
6.
Takeda A, Koyama I, Shimada H, Ochiai T. Titration of serum p53 autoantibodies in patients with colorectal cancer and the clinical significance of post-operative monitoring. Nippon Daicho Komonbyo Gakkai Zasshi. 2007;60:198–204.CrossRef
7.
8.
Naito A, Hiwasa T, Tanabe N, Sanada TJ, Sugiura T, Shigeta A, Terada J, Takizawa H, Kashiwado K, Sakao S, et al. Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension. PLoS ONE. 2019;14:e0211377 (PMID: 30759165).CrossRefPubMedPubMedCentral
9.
10.
Shimada H, Shiratori T, Yasuraoka M, Kagaya A, Kuboshima M, Nomura F, Takiguchi M, Ochiai T, Matsubara H, Hiwasa T. Identification of makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma. BMC Cancer. 2009;9:1–9 (PMID: 19604354).CrossRef
11.
Machida T, Kubota M, Kobayashi E, Iwadate Y, Saeki N, Yamaura A, Nomura F, Takiguchi M, Hiwasa T. Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX). J Transl Med. 2015;13:71 (PMID: 25890248).CrossRefPubMedPubMedCentral
12.
Wang H, Zhang XM, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kimura R, Mine S, Kamitsukasa I, Wada T, et al. Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget. 2018;9:5600–13 (PMID: 29464021).CrossRefPubMed
13.
Yoshida Y, Zhang XM, Wang H, Machida T, Mine S, Kobayashi E, Adachi A, Matsutani T, Kamitsukasa I, Wada T, et al. Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. Heliyon. 2020;6:e04661 (PMID: 32904265).CrossRefPubMedPubMedCentral
14.
Li SY, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, Machida T, Maezawa Y, Takemoto M, Yokote K, et al. Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Sci Rep. 2021;11:13450 (PMID: 34188129).CrossRefPubMedPubMedCentral
15.
16.
Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683–94 (PMID: 11463392).CrossRefPubMed
17.
Jiang P, Du W, Heese K, Wu M. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol. 2006;26:9071–82 (PMID: 17000778).CrossRefPubMedPubMedCentral
18.
Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053–8 (PMID: 10807576).CrossRefPubMed
19.
Shimada H, Liu TL, Ochiai T, Shimizu T, Haupt Y, Hamada H, Abe T, Oka M, Takiguchi M, Hiwasa T. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33ING1 in T.Tn human esophageal carcinoma cells. Oncogene. 2002;21:1208–16.CrossRefPubMed
20.
Shinmen N, Koshida T, Kumazawa T, Sato K, Shimada H, Matsutani T, Iwadate Y, Takiguchi M, Hiwasa T. Activation of NFAT signal by p53–K120R mutant. FEBS Lett. 2009;583:1916–22 (PMID: 19416725).CrossRefPubMed
21.
Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013;2: e71 (PMID: 24042735).CrossRefPubMedPubMedCentral
22.
Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, Fu CG, Takenoue T, Tsuruo T, Muto T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer. 1998;78:986–92 (PMID: 9792140).CrossRefPubMedPubMedCentral
23.
24.
He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol. 2005;22:104–16 (PMID: 15356280).CrossRefPubMed
25.
Jäger D, Stockert E, Scanlan MJ, Güre AO, Jäger E, Knuth A, Old LJ, Chen YT. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res. 1999;59:6197–204 (PMID: 10626813).PubMed
26.
Shimada H, Yajima S, Oshima Y, Hiwasa T, Tagawa M, Matsushita K, Nomura F. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus. 2012;9:131–40.CrossRef
27.
Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet. 1996;14:415–20 (PMID: 8944021).CrossRefPubMed
28.
Guérillon C, Larrieu D, Pedeux R. ING1 and ING2: multifaceted tumor suppressor genes. Cell Mol Life Sci. 2013;70:3753–72 (PMID: 23412501).CrossRefPubMed
29.
Jacquet K, Binda O. ING proteins: Tumour suppressors or oncoproteins. Cancers (Basel). 2021;13:2110 (PMID: 33925563).CrossRefPubMed
30.
Bose P, Thakur S, Thalappilly S, Ahn BY, Satpathy S, Feng X, Suzuki K, Kim SW, Riabowol K. ING1 induces apoptosis through direct effects at the mitochondria. Cell Death Dis. 2013;4: e788 (PMID: 24008732).CrossRefPubMedPubMedCentral
31.
Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM, Gudkov AV. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature. 1998;391:295–8 (PMID: 9440695).CrossRefPubMed
32.
Cheung KJ Jr, Li G. p33ING1 enhances UVB-induced apoptosis in melanoma cells. Exp Cell Res. 2002;279:291–8 (PMID: 12243754).CrossRefPubMed
33.
Kataoka H, Bonnefin P, Vieyra D, Feng X, Hara Y, Miura Y, Joh T, Nakabayashi H, Vaziri H, Harris CC, Riabowol K. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res. 2003;63:5785–92 (PMID: 14522900).PubMed
34.
Helbing CC, Veillette C, Riabowol K, Johnston RN, Garkavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res. 1997;57:1255–8 (PMID: 9102209).PubMed
35.
Coles AH, Liang H, Zhu Z, Marfella CGA, Kang J, Imbalzano AN, Jones SN. Deletion of p37 Ing1 in mice reveals a p53-independent role for Ing1 in the suppression of cell proliferation, apoptosis, and tumorigenesis. Cancer Res. 2007;67:2054–61 (PMID: 17332334).CrossRefPubMedPubMedCentral
36.
Kobayashi S, Hiwasa T, Arasawa T, Kagaya A, Ishii S, Shimada H, Ito M, Suzuki M, Kano M, Rahmutulla B, et al. Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library. Oncotarget. 2018;9:18559–69 (PMID: 29719626).CrossRefPubMedPubMedCentral
Metadata
Title
Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels
Authors
Takahiro Arasawa
Takaki Hiwasa
Akiko Kagaya
Tetsuro Maruyama
Masaya Uesato
Masayuki Kano
Sohei Kobayashi
Hirotaka Takizawa
Katsuro Iwase
Fumio Nomura
Kazuyuki Matsushita
Hisahiro Matsubara
Publication date
01-12-2023

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Metabolic syndrome and the risk of severe cancer events: a longitudinal study in Japanese workers

Research

Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity

Research

Clinical retrospective analysis with a predictive model for diffused-tenosynovial giant cell tumors of the temporomandibular joint

Research

Associations of financial toxicity with symptoms and unplanned healthcare utilization among cancer patients taking oral chemotherapy at home: a prospective observational study

Research

The impact and outcomes of cancer-macrophage fusion

Research

MicroRNA-188-5p inhibits hepatocellular carcinoma proliferation and migration by targeting forkhead box N2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits